Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06849544
PHASE2

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Sponsor: Clinton Bahler

View on ClinicalTrials.gov

Summary

This study is being done to compare how well Zopocianine (OTL78) in combination with Near InfraRed (NIR) fluorescent imaging may improve the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer.

Official title: Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection (Zopocianine), a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent, for the Intraoperative Imaging of Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

22

Start Date

2025-04-02

Completion Date

2026-06

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

0.03mg/kg ZOPOCIANINE given day of surgery

A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection

DRUG

0.06mg/kg ZOPOCIANINE given day of surgery

A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection

DRUG

0.03mg/kg ZOPOCIANINE given day prior to surgery

A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection

DRUG

0.06mg/kg ZOPOCIANINE given days prior to surgery

A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection

Locations (3)

Indiana University Health North Hospital

Carmel, Indiana, United States

Indiana University Health Methodist Hospital

Indianapolis, Indiana, United States

Indiana University School of Medicine

Indianapolis, Indiana, United States